Gifts, Drug Samples, and other Items Given to Medical Specialists by Pharmaceutical Companies

Journal of Bioethical Inquiry

Volumn 3, Issue 3, 2006, Pages 139-148

  McNeill, Paul M ^a   Kerridge, Ian H ^b   Arciuli, Catherine ^b   Henry, David A ^c   Macdonald, Graham J ^d   Day, Richard O ^a   Hill, Suzanne R ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Code of Conduct; Gifts; Medical specialists

Indexed keywords

EID: 45949105947     PISSN: 11767529     EISSN: 18724353     Source Type: Journal    
DOI: 10.1007/s11673-006-9019-0     Document Type: Article

References (31)

1. Australian Pharmaceutical Manufacturers’ Association (2000). Edition 13 Code of Conduct of the Australian Pharmaceutical Manufacturers’ Association, 1999 December (effective 1 January 2000) with amendments (adopted September 2000). Deakin, ACT, Australia: Medicines Australia.
2. D. Blumenthal Doctors and drug companies New England Journal of Medicine 2004 351 18 1885 1890 15509823 10.1056/NEJMhpr042734 1:CAS:528:DC%2BD2cXptFCnsr8%3D
3. H. Brody The company we keep: Why physicians should refuse to see pharmaceutical representatives Annals of Family Medicine 2005 3 1 82 85 15671196 10.1370/afm.259
4. F. Caamano A. Figueiras J.J. Gestal-Otero Influence of comercial information on prescription quantity in primary care European Journal of Public Health 2002 12 187 191 12232957 10.1093/eurpub/12.3.187
5. J. Collier I. Iheanacho The pharmaceutical industry as informant Lancet 2002 360 1405 1409 12424005 10.1016/S0140-6736(02)11394-8
6. E. Doran I.K. Kerridge P.M. McNeill D.A. Henry Empirical uncertainty and moral contest: A qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia Social Science & Medicine 2005 62 6 1510 1519 10.1016/j.socscimed.2005.07.037
7. R.V. Gibbons F.J. Landry D.L. Blouch D.L. Jones F.K. Williams C.R. Lucey et al. A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts Journal of General Internal Medicine 1998 13 151 154 9541370 10.1046/j.1525-1497.1998.00048.x 1:STN:280:DyaK1c3gtVCnsQ%3D%3D
8. D. Griffith Reasons for not seeing drug representatives British Medical Journal 1999 319 7202 69 70 10398608 1:STN:280:DyaK1MzivVOltQ%3D%3D
9. K.E. Groves I. Sketris S.E. Tett Prescription drug samples – Does this marketing strategy counteract policies for quality use of medicines? Journal of Clinical Pharmacy and Therapeutics 2003 28 4 259 271 12911677 10.1046/j.1365-2710.2003.00481.x 1:STN:280:DC%2BD3sznslGjtw%3D%3D
10. D.A. Henry E. Doran I.H. Kerridge S.R. Hill P.M. McNeill R.O. Day Ties that bind: Multiple relationships between clinical researchers and the pharmaceutical industry Archives of Internal Medicine 2005 165 2493 2496 16314546 10.1001/archinte.165.21.2493
11. D.A. Henry I.H. Kerridge S.R. Hill P.M. McNeill E. Doran D.A. Newby et al. Medical specialists and pharmaceutical industry-sponsored research: A survey of Australian experience Medical Journal of Australia 2005 182 11 557 560 15938681
12. D. Katz A.L. Caplan J.F. Merz All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift giving American Journal of Bioethics 2003 3 3 39 46 14594489 10.1162/15265160360706552
13. I.H. Kerridge J. Maguire D.A. Newby P.M. McNeill D. Henry S. Hill et al. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations Internal Medicine Journal 2005 35 4 206 210 15836497 10.1111/j.1444-0903.2004.00799.x 1:STN:280:DC%2BD2M3gt1yktg%3D%3D
14. P.A. Komesaroff Ethical issues in the relationship with industry: An ongoing challenge. New guidelines open for public comment Journal of Paediatrics Child Health 2005 41 558 560 10.1111/j.1440-1754.2005.00719.x 1:STN:280:DC%2BD28%2FhtlOjsQ%3D%3D
15. P.R. Mansfield Banning all drug promotion is the best option pending major reforms Journal of Bioethical Inquiry 2005 2 2 75 81 16317866 10.1007/BF02448846
16. D.O. Martin H. Austin An efficient program for computing conditional maximum likelihood estimates and exact confidence limits for a common odds ratio Epidemiology 1991 2 5 359 362 1742385 10.1097/00001648-199109000-00008 1:STN:280:By2D2srotVQ%3D
17. McNeill P. M., Kerridge I. H., Henry D. A., Stokes B., Hill S. R., Newby D., et al. The giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Internal Medicine Journal, 36(9), 571–578.
18. Medicines Australia, Code of Conduct, Edition 14, January 2003.
19. Medicines Australia, Code of Conduct, Edition 14, Guidelines, Version 3 (effective 24 September 2004). Deakin, ACT, Australia: Medicines Australia.
20. Medicines Australia, Code of Conduct, Edition 15, given interim authorisation April 2006. Final authorisation expected June 2006. From correspondence with Medicines Australia.
21. R. Moynihan Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement British Medical Journal 2003 326 7400 1189 1192 12775621 10.1136/bmj.326.7400.1189
22. J. Robertson J.L. Fryer D.L. O’Connell A. Sprogis D.A. Henry The impact of specialists on prescribing by general practitioners Medical Journal of Australia 2001 175 8 407 411 11700832 1:STN:280:DC%2BD3MnkvVKrug%3D%3D
23. R. Smith Medical journals and pharmaceutical companies: Uneasy bedfellows British Medical Journal 2003 326 1202 1205 12775625 10.1136/bmj.326.7400.1202
24. M.A. Steinman M.G. Shlipak S.J. McPhee Of principles and pens: attitudes and practices of medical house staff toward pharmaceutical industry promotions American Journal of Medicine 2001 10 7 551 557 10.1016/S0002-9343(01)00660-X
25. D. Stryer L.A. Bero Characteristics of materials distributed by drug companies. An evaluation of appropriateness Journal of General Internal Medicine 1996 11 10 575 583 8945688 1:STN:280:ByiC3c7hs1U%3D
26. The Australian Medical Association. Doctors’ relationships with the pharmaceutical industry (2002). http://www.ama.com.au/web.nsf/doc/WEEN-5GJ7MH (last accessed May 2006).
27. The Royal Australasian College of Physicians (1999). Ethical guidelines in the relationship between physicians and the pharmaceutical industry (2nd ed.). Sydney: The Royal Australasian College of Physicians.
28. The Royal Australasian College of Physicians (2006). Guidelines for ethical relationships between physicians and industry (3rd ed.). Sydney: The Royal Australasian College of Physicians (May).
29. C. Watkins L. Moore I. Harvey P. Carthy Characteristics of general practitioners who frequently see drug company representatives: National cross sectional study British Medical Journal 2003 326 1178 1179 12775618 10.1136/bmj.326.7400.1178
30. A. Wazana Physicians and the Pharmaceutical industry: is a gift ever just a gift Journal of the American Medical Association 2000 283 3 373 380 10647801 10.1001/jama.283.3.373 1:STN:280:DC%2BD3c7ht1ehtQ%3D%3D
31. A. Wazana A. Granich F. Primeau N.H. Bhanji M. Jalbert Using the literature in developing McGill’s guidelines for interactions between residents and the pharmaceutical industry Academic Medicine 2004 79 11 1033 1040 15504767 10.1097/00001888-200411000-00004